Home
/
Lyra Therapeutics, Inc.
/
Financials
/
Quarterly
Lyra Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Lyra Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$25.0K
Nov 12, 2025
Q2
2025
Jun 30, 2025
$183.0K
Aug 12, 2025
Q1
2025
Mar 31, 2025
$183.0K
May 6, 2025
Q3
2025
Sep 30, 2024
$195.0K
Nov 12, 2025
Q2
2025
Jun 30, 2024
$598.0K
Aug 12, 2025
Q1
2025
Mar 31, 2024
$532.0K
May 6, 2025
Q3
2024
Sep 30, 2023
$544.0K
Nov 12, 2024
Q2
2024
Jun 30, 2023
$458.0K
Aug 14, 2024
Q1
2024
Mar 31, 2023
$410.0K
Apr 30, 2024
Q3
2023
Sep 30, 2022
$359.0K
Nov 7, 2023
Q2
2023
Jun 30, 2022
$525.0K
Aug 8, 2023
Q1
2023
Mar 31, 2022
$468.0K
May 12, 2023
Q3
2022
Sep 30, 2021
$14.0K
Nov 8, 2022
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($5.98M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($7.44M)
Aug 12, 2025
Q3
2025
Jun 30, 2025
($7.44M)
Nov 12, 2025
Q3
2025
Mar 31, 2025
($8.55M)
Nov 12, 2025
Q2
2025
Mar 31, 2025
($8.55M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($8.55M)
May 6, 2025
Q3
2025
Sep 30, 2024
($11.87M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($48.13M)
Aug 12, 2025
Q3
2025
Jun 30, 2024
($48.13M)
Nov 12, 2025
Q3
2025
Mar 31, 2024
($22.45M)
Nov 12, 2025
Q2
2025
Mar 31, 2024
($22.45M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($22.45M)
May 6, 2025
Q3
2024
Sep 30, 2023
($15.65M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($15.62M)
Aug 14, 2024
Q3
2024
Jun 30, 2023
($15.62M)
Nov 12, 2024
Q2
2024
Mar 31, 2023
($16.26M)
Aug 14, 2024
Q1
2024
Mar 31, 2023
($16.26M)
Apr 30, 2024
Q3
2024
Mar 31, 2023
($16.26M)
Nov 12, 2024
Q3
2023
Sep 30, 2022
($14.77M)
Nov 7, 2023
Q2
2023
Jun 30, 2022
($14.37M)
Aug 8, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($6.24M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($8.83M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($8.84M)
May 6, 2025
Q3
2025
Sep 30, 2024
($12.44M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($48.97M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($23.52M)
May 6, 2025
Q3
2024
Sep 30, 2023
($16.83M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($16.50M)
Aug 14, 2024
Q1
2024
Mar 31, 2023
($17.31M)
Apr 30, 2024
Q3
2023
Sep 30, 2022
($14.83M)
Nov 7, 2023
Q2
2023
Jun 30, 2022
($14.40M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($11.93M)
May 12, 2023
Q3
2022
Sep 30, 2021
($11.08M)
Nov 8, 2022
Q2
2022
Jun 30, 2021
($11.07M)
Nov 2, 2022
Q1
2022
Mar 31, 2021
($7.83M)
Nov 2, 2022
Q3
2021
Sep 30, 2020
($6.36M)
Nov 9, 2021
Q2
2021
Jun 30, 2020
($4.55M)
Aug 9, 2021
Q1
2021
Mar 31, 2020
($4.25M)
May 11, 2021
Q3
2020
Sep 30, 2019
($4.23M)
Nov 10, 2020
Q2
2020
Jun 30, 2019
($4.28M)
Aug 5, 2020